FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 THE BETASERON CHANNEL: 37 TIPS
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Friday

 

Vitamin D Levels Appear to Be Robust Predictor of MS Progression

Higher vitamin D levels in persons with multiple sclerosis (MS) were associated with a lower degree of MS activity, magnetic resonance imaging lesion load, brain atrophy, and disease progression during 5 years of follow-up in the Betaferon/Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT) trial (Ascherio A et al. JAMA Neurol. doi:10.1001/jamaneurol.2013.5993 [published online January 20, 2014]).
Some 465 patients with clinically isolated syndrome (their first neurological episode, caused by inflammation or demyelination of nerve tissue) were randomized to early vs late treatment with interferon beta-1b (IFNB-1b). Compared with those who had 25-hydroxyvitamin D serum concentrations less than 50 nmol/L in the first 12 months following their first neurological episode, those with serum levels of 50 nmol/L or greater had a significantly lower rate of new active lesions and relapse, a significantly lower yearly increase in T2 lesion volume, and lower disability during the following 4 years.
read more